Preclinical data indicate that targeting oxidative stress pathways may sensitize tumors to immunotherapy by enhancing antigen presentation and reversing immune evasion, but clinical trials specifically focused on CDH1-mutant LBC are lacking [9]. The gene discussed is CDH1; the disease is CDH1-related diffuse gastric and lobular breast cancer syndrome.